Current objectives regarding treatment of acute myeloid leukemia (AML) include achieving
complete remission (CR) by clinicopathological criteria followed by interrogation for the …

Acute myeloid leukemia (AML) is a hematological malignancy characterized by cytogenetic
and genomic alterations. Up to now, combination chemotherapy remains the standard …

The treatment landscape of acute myeloid leukemia (AML) is evolving, with promising
therapies entering clinical translation, yet patient responses remain heterogeneous, and …

Background Although induction chemotherapy results in remission in many older patients
with acute myeloid leukemia (AML), relapse is common and overall survival is poor …

Acute myeloid leukemia (AML) is a heterogeneous clonal disease associated with a dismal
survival, partly due to the frequent occurrence of relapse. Many patient-and leukemia …

Acute myeloid leukemia (AML) is a common hematological disorder with heterogeneous
nature that resulted from blocked myeloid differentiation and an enhanced number of …

Measurable residual disease (MRD) detected by multiparametric flow cytometry (MFC) is
associated with unfavorable outcome in patients with AML. A simple, broadly applicable …

In acute myeloid leukemia (AML) many patients experience relapse, despite the
achievement of morphological complete remission; therefore, conventional morphologic …

Rapid and accurate diagnosis of acute myeloid leukemia (AML) remains a significant
challenge, particularly in the context of myelodysplastic syndrome (MDS) or MDS …

Acute myeloid leukemia (AML) is a hematological cancer that mainly affects the elderly.
Although complete remission (CR) is achieved for the majority of the patients after induction …